spinocerebellar ataxia
Conditions
Interventions
magstim rapid system MRS1000/30
Sponsors
Department of Neurology and Clinical Pharmacology, Ehime University Graduate School of Medicine
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Spinocerebellar ataxia cases who agreed to participate in this study
Exclusion criteria
Exclusion criteria: Patients disagreed to this study Who have been regarded to be inappropriate to participate in the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| SARA, ICARS, gait evaluation, stabilometry(before treatment, at 1, 2, 3 weeks, 2, 4, 6, 8, 10 and 12 months after treatment) | — |
Secondary
| Measure | Time frame |
|---|---|
| MMSE, HDS-R(before treatment, at 3 weeks, 6 and 12 months after treatment) | — |
Countries
Japan
Contacts
Public ContactNoriyuki Miyaue
Ehime University Graduate School of Medicine Department of Neurology and Clinical Pharmacology
Outcome results
None listed